March 12 (Reuters) - U.S. drugmakers Johnson & Johnson (JNJ.N), opens new tab and Eli Lilly (LLY.N), opens new tab increased spending on security for their top executives in 2024, citing increased ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

It will be available in Europe and the U.K. in March in either black or silver colors, and it’s expected to arrive in the U.S. soon after, for $1,499. Granted, that’s not exactly an impulse ...

When you think of the best K-dramas, Extraordinary Attorney Woo, Under the Queen’s Umbrella, and Little Women may be on your radar. But there's also a rich K-drama history to explore.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...